AstraZeneca’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

See the latest Daiichi Sankyo Co Ltd stock price (4568:XTKS), related news, valuation, dividends and more to help you make your investing decisions.

How has Daiichi Sankyo's total revenue grown this year? Daiichi Sankyo's total revenue was 484,840.00 in the previous quarter and 518,689.00 in the latest quarter.

Japan’s Daiichi Sankyo plans to conduct an absorption-style merger of two wholly owned manufacturing companies in a bid to leverage its dominance in the antibody-drug conjugate (ADC) space.

An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...

TOKYO, January 31, 2025--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer ...

Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and com ...

(RTTNews) - Daiichi Sankyo (DSKYF.PK) and Merck & Co Inc. (MRK) said that they have reached a global development and commercialization agreement worth up to $22 billion for three of Daiichi Sankyo ...

Daiichi plans to rack up four or five indications over the next few years, making speed, efficiency and synergy more important than ever, Keller said. RELATED: Daiichi Sankyo pulls out of U.S ...

Daiichi Sankyo Co., Ltd. (hereafter, Daiichi Sankyo) and UC San Francisco (UCSF) have established a drug-discovery collaboration focused on developing novel therapeutics and molecular diagnostics for ...

To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch. Please see accompanying full Prescribing Information, including ...